Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2021-04-10 Regulatory Filings
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes detailed information about the securities to be registered, the plans under which they are issued, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive registration statement.
2021-04-10 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable for more specific classification.
2021-04-05 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus and a sales agreement prospectus supplement for offerings up to $250 million. The text contains detailed information about the securities to be offered, risk factors, use of proceeds, and legal matters, typical of a registration statement for capital raising. This is not an earnings release, annual report, or any other financial report but a capital/financing update related to securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or notice.
2021-03-31 English
10-K
Annual Report FY 2020
2021-03-31 English
FORM 3 SUBMISSION
Director's Dealing
2021-03-19 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 15, 2021. The content describes the appointment of a new Chief Financial Officer, Paul Little, including details about his background, employment terms, and severance provisions. The key item is Item 5.02, which relates to the departure and appointment of directors or certain officers. There is no financial data or report content, only management change information. Therefore, this filing is best classified as Board/Management Information (MANG). The document length (7810 characters) supports it being a full filing rather than a brief announcement or certification.
2021-03-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.